Trial Profile
An open label, randomized, phase II study of AS1404 in combination with carboplatin and paclitaxel in patients with platinum-sensitive recurrent ovarian epithelial cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Vadimezan (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Antisoma
- 23 Sep 2007 Interim results presented at ECCO 2007.
- 11 Nov 2005 New trial record.